Qube Research & Technologies (QRT)
AMRX icon

Qube Research & Technologies (QRT)’s Amneal Pharmaceuticals AMRX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.14M Sell
181,223
-258,444
-59% -$3.54M ﹤0.01% 1875
2026
Q1 		$5.47M Sell
439,667
-771,099
-64% -$10.4M 0.01% 1595
2025
Q4 		$15.3M Sell
1,210,766
-546,887
-31% -$6.26M 0.02% 1064
2025
Q3 		$17.6M Sell
1,757,653
-153,209
-8% -$1.38M 0.02% 960
2025
Q2 		$15.5M Buy
1,910,862
+144,897
+8% +$1.09M 0.02% 1027
2025
Q1 		$14.8M Buy
1,765,965
+467,959
+36% +$3.91M 0.02% 896
2024
Q4 		$10.3M Buy
1,298,006
+46,247
+4% +$388K 0.01% 1069
2024
Q3 		$10.4M Buy
1,251,759
+610,852
+95% +$4.78M 0.02% 1020
2024
Q2 		$4.07M Buy
640,907
+150,033
+31% +$952K 0.01% 1356
2024
Q1 		$2.97M Buy
490,874
+470,323
+2,289% +$2.65M ﹤0.01% 1530
2023
Q4 		$125K Buy
+20,551
New +$91.5K ﹤0.01% 3018
2023
Q2 		– Sell
-73,265
Closed -$102K – 2364
2023
Q1 		$102K Buy
73,265
+41,709
+132% +$83K ﹤0.01% 2119
2022
Q4 		$62.8K Buy
+31,556
New +$70.7K ﹤0.01% 2101
2021
Q3 		– Sell
-34,780
Closed -$178K – 2156
2021
Q2 		$178K Sell
34,780
-29,910
-46% -$170K ﹤0.01% 1823
2021
Q1 		$435K Buy
+64,690
New +$359K 0.01% 1254
2020
Q4 		– Sell
-24,852
Closed -$96K – 1779
2020
Q3 		$96K Sell
24,852
-100,732
-80% -$431K ﹤0.01% 1495
2020
Q2 		$598K Buy
+125,584
New +$517K 0.01% 1040
2020
Q1 		– Sell
-40,851
Closed -$197K – 1101
2019
Q4 		$197K Buy
+40,851
New +$142K 0.01% 1398

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AMRX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Amneal Pharmaceuticals (AMRX) stake by 59% in Q2 2026, selling an estimated $3.54M and leaving 181,223 shares worth $3.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1875.

Qube Research & Technologies (QRT) first reported a position in AMRX in Q4 2019 and has held it in 18 quarters since. The position peaked at $17.6M in Q3 2025. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Qube Research & Technologies (QRT) held 181,223 shares of Amneal Pharmaceuticals worth $3.14M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 258,444 Amneal Pharmaceuticals shares in Q2 2026, an estimated $3.54M.
  • Amneal Pharmaceuticals made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1875 holding.
  • Qube Research & Technologies (QRT) first reported a position in Amneal Pharmaceuticals in Q4 2019 and has held it in 18 quarters since.
  • Qube Research & Technologies (QRT)'s Amneal Pharmaceuticals position peaked at $17.6M in Q3 2025.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.